PMID- 27256336
OWN - NLM
STAT- MEDLINE
DCOM- 20170328
LR  - 20181113
IS  - 1941-6636 (Electronic)
VI  - 47
IP  - 4
DP  - 2016 Dec
TI  - Effect of Insulin and Metformin Combination Treatment on Colon Adenoma and 
      Advanced Adenoma Among DM II.
PG  - 404-408
AB  - BACKGROUND: The risk for colorectal adenoma and advanced adenoma among diabetes 
      mellitus II (DM II) has been debated to differ with the type of anti-diabetic 
      therapy. Insulin increases whereas metformin decreases the risk for colon adenoma 
      (Ad) and advanced Ad (AAd). There have been no studies to evaluate the effect of 
      combination treatment with insulin and metformin on colon Ad and AAd. METHODS: 
      The retrospective study included DM II patients undergoing screening colonoscopy. 
      Subjects with incomplete colonoscopy, poor bowel preparation, personal history of 
      colorectal cancer (CRC)/inflammatory bowel disease/hereditary nonpolyposis 
      colorectal cancer/familial adenomatosis polyposis/colectomy or family history of 
      CRC were excluded. Subjects were categorized into group 1 (insulin only), group 2 
      (metformin only), group 3 (combination of insulin and metformin) and group 4 
      (miscellaneous). Group 4 was excluded from data analysis. Ad detection rate (ADR) 
      and advanced ADR (AADR) were calculated for each group. RESULTS: Three hundred 
      thirty-nine subjects composed the study group, with a mean age of 60.0 years and 
      male to female ratio of 1:1.4. Composite ADR and AADR for study population was 
      35.1 and 15.3 %, respectively. Groups 1, 2 and 3 were composed of 88 (26.0 %), 
      211 (62.2 %) and 40 (11.8 %) subjects, respectively. ADR for groups 1, 2 and 3 
      was 40.9, 33.2 and 32.5 %, respectively (p value = 0.413). AADR for groups 1, 2 
      and 3 was 18.2, 15.2 and 10.0 %, respectively (p value = 0.489). CONCLUSION: A 
      decremental trend was observed in ADR and AADR across group 1, group 2 and group 
      3 (p value >0.05).
FAU - Jain, Deepanshu
AU  - Jain D
AD  - Internal Medicine Department, Albert Einstein Medical Center, 5401 Old York Road, 
      Philadelphia, PA, 19141, USA. deepanshu.jain.25@gmail.com.
FAU - Chhoda, Ankit
AU  - Chhoda A
AD  - Internal Medicine Department, Lok Nayak Hospital, Delhi, 110002, India.
FAU - Uribe, Jorge
AU  - Uribe J
AD  - Division of Gastroenterology, Internal Medicine Department, Albert Einstein 
      Medical Center, Philadelphia, PA, 19141, USA.
LA  - eng
PT  - Journal Article
PL  - United States
TA  - J Gastrointest Cancer
JT  - Journal of gastrointestinal cancer
JID - 101479627
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adenoma/*drug therapy
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Colorectal Neoplasms/*drug therapy
MH  - Diabetes Complications/*drug therapy
MH  - Early Detection of Cancer
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/administration & dosage
MH  - Insulin/administration & dosage
MH  - Male
MH  - Metformin/administration & dosage
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Adenoma
OT  - Advanced adenoma
OT  - Diabetes mellitus type II
OT  - Insulin
OT  - Metformin
EDAT- 2016/06/04 06:00
MHDA- 2017/03/30 06:00
CRDT- 2016/06/04 06:00
PHST- 2016/06/04 06:00 [pubmed]
PHST- 2017/03/30 06:00 [medline]
PHST- 2016/06/04 06:00 [entrez]
AID - 10.1007/s12029-016-9842-4 [pii]
AID - 10.1007/s12029-016-9842-4 [doi]
PST - ppublish
SO  - J Gastrointest Cancer. 2016 Dec;47(4):404-408. doi: 10.1007/s12029-016-9842-4.